A
Ascendis Pharma A/S (ASND)
NMS – Real Time Price. Currency in USD
237.65
-1.02 (-0.43%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
237.65
-1.02 (-0.43%)
At close: May 12, 2026, 4:00 PM EDT
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
| Name | Position |
|---|---|
| Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development |
| Dr. Stina Singel M.D., Ph.D. | Executive VP & Head of Clinical Development for Oncology |
| Mr. Chad Fugure | Vice President of Investor Relations |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality |
| Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology |
| Mr. Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer |
| Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 6-K | d121855d6k.htm |
| 2026-04-21 | 6-K | d139196d6k.htm |
| 2026-04-20 | 8-A12B/A | d51268d8a12ba.htm |
| 2026-04-20 | 6-K | d620541d6k.htm |
| 2026-04-16 | 6-K | d134243d6k.htm |
| 2026-04-08 | 6-K | d118310d6k.htm |
| 2026-04-07 | 6-K | d121667d6k.htm |
| 2026-03-30 | 6-K | d127945d6k.htm |
| 2026-03-24 | 6-K | d192884d6k.htm |
| 2026-03-17 | 6-K | d95087d6k.htm |